Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc.

OOTC:FNCHQ
10.35
USD
-0.15
(-1.43%)
-8.82EPS
2.20MMarket Cap

Total Valuation

USD

As of June 30, 2024, Finch Therapeutics Group, Inc. carries a market capitalization of 2.20M, placing it among publicly traded companies globally. Its enterprise value stands at 15.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.20M
Enterprise Value15.15M

Important Dates

Finch Therapeutics Group, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

Earnings Date11/12/2026

Share Statistics

As of June 30, 2024, Finch Therapeutics Group, Inc. has 1.61M shares outstanding.

Shares Outstanding1.61M

Valuation Ratios

These figures are as of June 30, 2024.

PB Ratio0.15
P/TBV Ratio0.15
P/FCF Ratio-0.12
P/OCF Ratio-0.12

Financial Position

As of June 30, 2024, Finch Therapeutics Group, Inc. maintains a current ratio of 3.87, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

Current Ratio3.87
Quick Ratio3.59
Debt / Equity203.88
Debt / EBITDA-1.50

Financial Efficiency

Over the twelve months ended June 30, 2024, Finch Therapeutics Group, Inc. posted a negative return on equity (ROE) of -67.28, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.20, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 5.25, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-67.28
Return on Assets (ROA)-25.20
Employee Count5.25

Stock Price Statistics

USD

As of the close on September 23, 2026, Finch Therapeutics Group, Inc.'s stock has declined approximately 15.16% over the past 52 weeks. The 50-day moving average sits at 9.48, while the 200-day moving average is 11.52.

52-Week Price Change-15.16%
50-Day Moving Average9.48
200-Day Moving Average11.52

Income Statement

USD

Over the twelve months ended June 30, 2024, Finch Therapeutics Group, Inc. generated - - in revenue and converted that into -14.17M in net income, yielding earnings per share of -8.82. EBITDA reached -19.32M, while operating income came in at -19.69M.

Operating Income-19.69M
Pretax Income-14.17M
Net Income-14.17M
EBITDA-19.32M
EBIT-19.50M
Earnings Per Share (EPS)-8.82

Balance Sheet

USD

As of June 30, 2024, Finch Therapeutics Group, Inc. holds 16.04M in cash and equivalents against 28.99M in total debt, resulting in a net debt position of -16.03M. Total book value stands at 14.22M, with working capital of 12.82M providing operational flexibility.

Cash & Cash Equivalents16.04M
Total Debt28.99M
Net Debt-16.03M
Equity (Book Value)14.22M
Book Value Per Share8.85
Working Capital12.82M

Cash Flow

USD

Finch Therapeutics Group, Inc. produced -18.05M in operating cash flow over the twelve months ended June 30, 2024. After subtracting 14,000.00 in capital expenditures, free cash flow totaled -18.04M - equivalent to -11.24 per share.

Operating Cash Flow-18.05M
Capital Expenditures14,000.00
Free Cash Flow-18.04M
FCF Per Share-11.24

Dividends & Yields

These figures cover the twelve months ended June 30, 2024. Free cash flow yield is negative at -820.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Finch Therapeutics Group, Inc. shareholders.

FCF Yield-820.19

Stock Splits

Finch Therapeutics Group, Inc.'s most recent stock split took place on June 12, 2023 with a 30:1 split ratio.

Last Split Date6/12/2023
Split Ratio30:1

Scores

As of June 30, 2024, Finch Therapeutics Group, Inc. has an Altman Z-Score of -12.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-12.08